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Background and aims: The current classification of diabetes into two main
forms (T1D and T2D) has been useful in delineating T1D as an insulin-
deficient form requiring insulin therapy but less useful for dissecting the het-
erogeneity of T2D. A refined classification could provide a powerful tool to
identify those at greatest risk of complications already at diagnosis and tailor
individualized treatment.
Materials and methods: We performed unsupervised clustering (k-means
and hierarchical) based on six variables (age, BMI, HbA1c, HOMA2-B,
HOMA2-IR and GAD auto-antibodies) in ANDIS, a Swedish cohort of
15,000 newly diagnosed diabetes patients. Disease progression, treatment
and development of complications were followed using medical records and
national registries. Risk of complications was analyzed using cox regression
with the largest cluster as reference. Genetic loci known to be associated with
T2D and related traits were analysed using MLE comparing each cluster to a
non-diabetic cohort from the same geographical region.
Results: ANDIS patients clustered into one GADA-positive cluster (re-
ferred to as SAID, Severe Autoimmune Diabetes) and four GADA-
negative clusters. This was replicated in three independent cohorts from
Sweden and Finland. Cluster 2 (SIDD, Severe Insulin Deficient Diabetes;
17.5% of patients) was characterized by early onset, insulin deficiency
and high HbA1c. During a mean follow-up of 4 years SIDD had higher
HbA1c, was more likely to be prescribed insulin and develop diabetic
retinopathy compared to other GADA-negative clusters. Cluster 3 (SIRD,
Severe Insulin Resistant Diabetes; 15.3%) had the highest risk of kidney
disease including CKD stage 3B (HR 3.30[2.67-4.08], p=3.6x10-28) and
macroalbuminuria/end-stage renal disease (ESRD; HR 2.40[1.69-3.42],
p=9.8x10-7). This was replicated in a cohort with longer follow-up
(SDR, mean 11 years), where SIRD had five-fold increased risk of
ESRD (HR 5.04[2.76-9.23], p=1.5x10-7). Cluster 4 (MOD, Mild Obese
Diabetes; 21.6%) and cluster 5 (MARD, Mild Age-Related Diabetes;
39.1%) showed only modest metabolic derangements. Using p<0.01 as
cut-off, no genetic variant was associated with all clusters. Strikingly,
the T2D-associated variant, rs7903146, in the TCF7L2 gene was associ-
ated with SIDD (OR 1.51[1.33-1.71], p=2.8x10-10), MOD (OR 1.38[1.21-
1.56], p=25.7x10-7) and MARD (OR 1.41 [1.28-1.55], p=1.1x10-12), but
not with SIRD (OR 1.00[0.87-1.15], p=0.86). A variant in IGF2BP2
(rs4402960) was associated with SIDD (OR 1.23[1.08-1.40], p=2.0x10-4)
and MARD (OR 1.22[1.11-1.33], p=2.1x10-6), but not with SIRD (OR
1.01[0.88-1.16], p=0.53) or MOD (OR 1.04[0.92-1.18], p=0.31).
Conclusion: This study provides a first step towards a more precise, clinically
useful, classification of diabetes representing an important step towards preci-
sion medicine in diabetes.
Supported by: Swedish Research Council, ERC, Novo Nordisk Foundation,
ALF
Disclosure: E. Ahlqvist: None.
250
Clustering on baseline clinical variables identifies subgroups of type 2
diabetes patients with different rate of progression over 18 months: a
DIRECT study
C.A. Brorsson1, H. Krogh Pedersen1, V. Gudmundsdottir1, A. Mari2, A.
Kurbasic3, A. Viñuela4, J. Fernandez5, A. Mahajan5, R. Gupta1, E.
Dermitzakis4, M. MacCarthy5, P. Franks3, E. Pearson6, S. Brunak1,7, for the
DIRECT Consortium;
1Department of Bioinformatics, Technical University of Denmark, Lyngby,
Denmark, 2Institue of Neuroscience - National Research Council, Padova,
Italy, 3Lund University, Malmö, Sweden, 4University of Geneva, Geneva,
Switzerland, 5University of Oxford, Oxford, 6University of Dundee,
Dundee, UK, 7University of Copenhagen, Copenhagen, Denmark.
Background and aims: Type 2 diabetes is characterized by a heterogeneous
presentation with varying degrees of insulin resistance and β-cell failure.
Taking advantage of the detailed clinical information collected for type 2
diabetes patients included in the DIRECT study, our aim was to characterize
inter-individual heterogeneity and identify subgroups with different presenta-
tions of diabetic phenotypes at baseline, and investigate the effect on the rate of
progression during follow-up. Genotyping data was used to evaluate genetic
differences between subgroups.
Materials andmethods: 836 newly diagnosed individuals were enrolled
in the DIRECT study. The clustering was based on 20 clinical vari-
ables from the baseline visit consisting of anthropometric, biochemical
and glycaemic modeling variables. We clustered the individuals using
an unsupervised, agglomerative clustering method. Diabetes progres-
sion was assessed using individual HbA1c slopes obtained from a
conditional linear mixed-model using data at 0, 9 and 18 month ad-
justed for weight, diabetes medication and baseline HbA1c. An extra
time-varying covariate defined to be 1 at baseline and zero for all
other visits was introduced to account for presence of effect from
baseline to subsequent visits. Linear regression models with cluster
membership as predictor was used to calculate effect, 95% CI and
p-values for differences between subgroups. A genetic risk score
(GRS) was calculated from the cumulative number of risk alleles of
65 published GWAS SNPs for type 2 diabetes.
Results: Full clinical data was available for 790 individuals. We identi-
fied three major patient subgroups that differed significantly in regards
to their baseline characteristics. The three groups could broadly be de-
scribed as insulin resistant (IR), β-cell deficient (βD), and mixed. The
most significant difference was seen in insulin sensitivity (ln(Matsuda),
beta (95% CI): Mixed= -0.61 (-0.68- -0.55), p=9.9*10-68; IR=-1.3 (-1.3-
-1.2), p=4.9*10-203) compared to the βD group, but also insulin secre-
tion, C-peptide, BMI, basal glucose, triglycerides and ALT (p<10-16).
The IR group was treated with significantly more metformin compared
to the βD group (% maximum dose: IR= 5.13 (1.79-8.47), p=0.003).
Investigating the rate of progression in HbA1c between baseline and 18
months showed that the IR group had the fastest progression compared
to the βD group, which had the slowest progression (change in HbA1c
(mmol/mol)/year: IR=0.77 (0.32-1.22), p=0.0008). There was no differ-
ence for the GRS constructed of 65 GWAS SNPs.
Conclusion:We have demonstrated that the newly diagnosed type 2 diabetes
cohort from DIRECT has a heterogeneous presentation of their diabetic phe-
notype at baseline. Clustering identified three major subgroups, driven by their
level of insulin resistance-related traits. The subgroups showed differences in
their rate of progression over 18 months with the insulin resistant group show-
ing the fastest progression.
Supported by: IMI Joint Undertaking n° 115317, FP7/2007-2013 and EFPIA
companies in kind
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Background and aims: Pancreatic autoantibody status may be used as a
biomarker to differentiate diabetes subtype. Single antibody positivity in indi-
viduals presenting at older age has uncertain significance, but has not been
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